Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 61 to 70 of 381

Type: Guidance`Remove $Type: Guidance filter`

Guidance and quality standards awaiting development
Title	Type
Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source [ID1417]	Technology appraisal guidance
Dabrafenib with trametinib for treating BRAF V600E mutation-positive advanced differentiated thyroid cancer after radioactive iodine and 1 or 2 VEGFR-targeted treatments	Technology appraisal guidance
Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838]	Technology appraisal guidance
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]	Technology appraisal guidance
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]	Technology appraisal guidance
Datopotamab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after osimertinib [TSID12418]	Technology appraisal guidance
Datopotamab deruxtecan with durvalumab and carboplatin for untreated TROP2-positive advanced non-small-cell lung cancer without actionable genomic alterations [ID6522]	Technology appraisal guidance
Datopotamab deruxtecan with durvalumab for treating triple-negative breast cancer when there is residual invasive disease after neoadjuvant systemic treatment and surgery [ID6643]	Technology appraisal guidance
DB-OTO for Hearing loss [ID6728]	Technology appraisal guidance
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years [ID3897]	Technology appraisal guidance

Results per page

10
25
50
All